Primary prevention of adverse gastroduodenal effects from short-term use of non-steroidal anti-inflammatory drugs by omeprazole 20 mg in healthy subjects: A randomized, double-blind, placebo-controlled study

Digestive Diseases and Sciences

Volumn 53, Issue 8, 2008, Pages 2059-2065

  Desai, Jay C ^a   Sanyal, Shefali M ^a   Goo, Tyralee ^a   Benson, Ariel A ^a   Bodian, Carol A ^a   Miller, Kenneth M ^a   Cohen, Lawrence B ^a   Aisenberg, James ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Anti ulcer agents; Dyspepsia; Non steroidal anti inflammatory agents; Peptic ulcer; Primary prevention; Proton pump inhibitors

Indexed keywords

NAPROXEN; OMEPRAZOLE; PLACEBO;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENDOSCOPIC BIOPSY; FEMALE; GASTRODUODENAL ULCER; HELICOBACTER PYLORI; HUMAN; HUMAN TISSUE; LOW DRUG DOSE; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; SHORT COURSE THERAPY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DOUBLE-BLIND METHOD; DUODENAL ULCER; DUODENOSCOPY; DYSPEPSIA; FEMALE; GASTROSCOPY; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; NAPROXEN; OMEPRAZOLE; PILOT PROJECTS; PROTON PUMP INHIBITORS; REFERENCE VALUES; STOMACH ULCER; TREATMENT OUTCOME;

EID: 46449100969     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-007-0127-4     Document Type: Article

References (48)

1. Lanas A, Perez-Aisa MA, Feu F et al (2005) A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 100(8):1685-1693
2. Wolfe MM, Lichtenstein DR, Singh G (1999) Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340(24):1888-1899
3. Henry D, Robertson J (1993) Nonsteroidal anti-inflammatory drugs and peptic ulcer hospitalization rates in New South Wales. Gastroenterology 104(4):1083-1091
4. Griffin MR, Piper JM, Daugherty JR et al (1991) Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114(4):257-263
5. Farkouh ME, Kirshner H, Harrington RA et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364(9435):675-684
6. Silverstein FE, Faich G, Goldstein JL et al (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284(10):1247-1255
7. Hawkey C, Talley NJ, Yeomans ND et al (2005) Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 100(5):1028-1036
8. Hooper L, Brown TJ, Elliott R et al (2004) The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 329(7472):948
9. Scheiman JM, Yeomans ND, Talley NJ et al (2006) Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 101(4):701-710
10. Laine L, Bombardier C, Hawkey CJ et al (2002) Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123(4):1006-1012
11. Garcia Rodriguez LA, Hernandez-Diaz S (2004) Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 159(1):23-31
12. Lanas A (2004) Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 20(3):321-331
13. Vonkeman HH, Fernandes RR, van der PJ et al (2007) Proton-pump inhibitors are associated with a reduced risk for bleeding and perforated gastroduodenal ulcers attributable to non-steroidal anti-inflammatory drugs: a nested case control study. Arthritis Res Ther 9(3):R52
14. Goldstein JL, Howard KB, Walton SM et al (2006) Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. Clin Gastroenterol Hepatol 4(11):1337-1345
15. Abraham NS, El Serag HB, Johnson ML et al (2005) National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. Gastroenterology 129(4):1171-1178
16. Sturkenboom MC, Burke TA, Dieleman JP et al (2003) Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology (Oxford) 42(Suppl 3):iii23-iii31
17. Lanas A, Ferrandez A (2007) Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging 24(2):121-131
18. Van Soest EM, Sturkenboom MC, Dielman JP, Verhamme KM, Siersema PD, Kuipers EJ (2007) Adherence to Gastroprotection and the Risk of NSAID-Related Upper Gastrointestinal Ulcers and Haemorrhage. Aliment Pharmacol Ther 26(2):265-275
19. Antman EM, Bennett JS, Daugherty A et al (2007) Use of nonsteroidal antiinflammatory drugs: an update for clinicians: a scientific statement from the American Heart Association. Circulation 115(12):1634-1642
20. Graham DJ (2006) COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA 296(13):1653-1656
21. Henry D, McGettigan P (2007) Selective COX-2 inhibitors: a promise unfulfilled? Gastroenterology 132(2):790-794
22. Yeomans ND, Tulassay Z, Juhasz L et al (1998) A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group. N Engl J Med 338(11):719-726
23. Hawkey CJ, Karrasch JA, Szczepanski L et al (1998) Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338(11):727-734
24. Cullen DJ, Seager JM, Holmes S et al (2000) Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 14(2):177-185
25. Pilotto A, Franceschi M, Leandro G et al (1997) The effect of Helicobacter pylori infection on NSAID-related gastroduodenal damage in the elderly. Eur J Gastroenterol Hepatol 9(10):951-956
26. Pilotto A, Franceschi M, Leandro G et al (2004) Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 20(10):1091-1097
27. Hansen JM, Hallas J, Lauritsen JM, Bytzer P (1996) Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 31(2):126-130
28. Rabeneck L, Cook KF, Wristers K et al (2001) SODA (severity of dyspepsia assessment): a new effective outcome measure for dyspepsia-related health. J Clin Epidemiol 54(8):755-765
29. Rabeneck L, Wristers K, Goldstein JL et al (2002) Reliability, validity, and responsiveness of severity of dyspepsia assessment (SODA) in a randomized clinical trial of a COX-2-specific inhibitor and traditional NSAID therapy. Am J Gastroenterol 97(1):32-39
30. Rabeneck L (2003) Measuring dyspepsia-related health in randomized trials: the Severity of Dyspepsia Assessment (SODA) and its use in treatment with NSAIDs and COX-2-specific inhibitors. Rheumatology (Oxford) 42(Suppl 3):iii32-iii39
31. Brown GJ, Yeomans ND (1999) Prevention of the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: the role of proton pump inhibitors. Drug Saf 21(6):503-512
32. Scheiman JM, Behler EM, Loeffler KM, Elta GH (1994) Omeprazole ameliorates aspirin-induced gastroduodenal injury. Dig Dis Sci 39(1):97-103
33. Bigard MA (1988) [Protective effect of omeprazole on gastric lesions induced by a single dose of aspirin in man]. Gastroenterol Clin Biol 12(10):770-771
34. Bianchi PG, Lazzaroni M, Petrillo M et al (1998) Prevention of gastroduodenal damage with omeprazole in patients receiving continuous NSAIDs treatment. A double blind placebo controlled study. Ital J Gastroenterol Hepatol 30(1):43-47
35. Oddsson E, Gudjonsson H, Thjodleifsson B (1992) Comparison between ranitidine and omeprazole for protection against gastroduodenal damage caused by naproxen. Scand J Gastroenterol 27(12):1045-1048
36. Daneshmend TK, Stein AG, Bhaskar NK, Hawkey CJ (1990) Abolition by omeprazole of aspirin induced gastric mucosal injury in man. Gut 31(5):514-517
37. Simon B, Elsner H, Muller P (1995) [Protective effect of omeprazole against low-dose acetylsalicylic acid. Endoscopic controlled double-blind study in healthy subjects] Arzneimittelforschung 45(6):701-703
38. Muller P, Fuchs W, Simon B (1997) [Studies on the protective effect of lansoprazole on human gastric mucosa against low-dose acetylsalicylic acid. An endoscopic controlled double-blind study]. Arzneimittelforschung 47(6):758-760
39. Bergmann JF, Chassany O, Simoneau G et al (1992) Protection against aspirin-induced gastric lesions by lansoprazole: simultaneous evaluation of functional and morphologic responses. Clin Pharmacol Ther 52(4):413-416
40. Cullen D, Bardhan KD, Eisner M et al (1998) Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther 12(2):135-140
41. Regula J, Butruk E, Dekkers CP et al (2006) Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. Am J Gastroenterol 101(8):1747-1755
42. Leandro G, Pilotto A, Franceschi M et al (2001) Prevention of acute NSAID-related gastroduodenal damage: a meta-analysis of controlled clinical trials. Dig Dis Sci 46(9):1924-1936
43. Laine L (2002) Gastrointestinal safety of coxibs and outcomes studies: what's the verdict? J Pain Symptom Manage 23(4 Suppl):S5-10
44. Goldstein JL, Aisenberg J, Lanza F et al (2006) A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65-75 years. Clin Ther 28(3):340-351
45. Ekström P, Carling L, Wetterhus S et al (1996) Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 31(8):753-758
46. Dorta G, Nicolet M, Vouillamoz D et al (1996) Effects of misoprostol on healing and prevention of biopsy-induced gastroduodenal lesions occurring during the administration of diclofenac to volunteers. Aliment Pharmacol Ther 10(4):563-569
47. James MW, Hawkey CJ (2003) Assessment of non-steroidal anti-inflammatory drug (NSAID) damage in the human gastrointestinal tract. Br J Clin Pharmacol 56(2):146-155
48. Prichard PJ, Yeomans ND, Mihaly GW et al (1985) Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. Gastroenterology 88(1 Pt 1):64-69